Browse by Phase
Phase 1 / Phase 2 Clinical Trials
Phase 1/2 combined trials evaluate both safety (Phase 1) and preliminary efficacy (Phase 2) in a single study protocol, often used to accelerate early development.
Total Trials
393
Recruiting Now
393
Top Conditions in Phase 1 / Phase 2
Frequently Asked Questions — Phase 1 / Phase 2 Trials
What are combined Phase 1/2 clinical trials?
Phase 1/2 trials are adaptive designs that evaluate both safety (Phase 1 objectives) and preliminary efficacy (Phase 2 objectives) within a single trial protocol. They are commonly used in oncology and rare disease research to accelerate development timelines. Dose escalation occurs in the Phase 1 portion, followed by expansion cohorts at the selected dose in the Phase 2 portion.
Why do sponsors combine Phase 1 and Phase 2?
Combining phases reduces development time and cost, particularly for conditions with high unmet need. For rare diseases or cancer indications, finding sufficient eligible patients can be challenging—a combined design uses the same patient pool more efficiently. Regulatory agencies including the FDA encourage adaptive designs to accelerate evidence generation for serious conditions.
How do I find Phase 1/2 trials I can join?
Phase 1/2 trials listed on ClinicalMetric are sourced from ClinicalTrials.gov and filtered by recruitment status. Each listing shows enrollment status, conditions studied, sponsor, participating sites, and estimated enrollment. Because Phase 1/2 trials often have narrow eligibility criteria, carefully review the protocol and discuss potential participation with your treating physician.
Active Phase 1 / Phase 2 Studies
NCT06634849 Phase 1, Phase 2
Recruiting
An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAI...
Condition
Advanced Solid Tumor
Enrollment
30 pts
Location
Australia
Sponsor
Pathios Therapeutics Pty Ltd
NCT06474455 Phase 1, Phase 2
Recruiting
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-...
Condition
Advanced Solid Tumors
Enrollment
156 pts
Location
China
Sponsor
Shanghai Hengrui Pharmaceutica
NCT05989958 Phase 1, Phase 2
Recruiting
The Safety ,Tolerability and Efficacy Study of HepaCure in Chinese Subjects with...
Condition
Acute on Chronic Hepatic Failure
Enrollment
92 pts
Location
China
Sponsor
Hexaell Biotech Co., Ltd.
NCT06688799 Phase 1, Phase 2
Recruiting
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases
Condition
Autoimmune Diseases
Enrollment
18 pts
Location
China
Sponsor
Beijing GoBroad Hospital
NCT04065399 Phase 1, Phase 2
Recruiting
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rea...
Condition
Acute Myeloid Leukemia
Enrollment
447 pts
Location
United States, Australia, Canada
Sponsor
Syndax Pharmaceuticals
NCT04172532 Phase 1, Phase 2
Recruiting
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual...
Condition
Locally Advanced Pancreatic Adenocarcinoma
Enrollment
92 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT05048901 Phase 1, Phase 2
Recruiting
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocri...
Condition
Neuroendocrine Tumors,Gastroenteropancreatic
Enrollment
49 pts
Location
Taiwan
Sponsor
National Health Research Insti
NCT06727630 Phase 1, Phase 2
Recruiting
A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma
Condition
Melanoma
Enrollment
40 pts
Location
China
Sponsor
Zhuhai Yufan Biotechnologies C
NCT05739864 Phase 1, Phase 2
Recruiting
Superdonor FMT in Patients With Ulcerative Colitis
Condition
Active Ulcerative Colitis
Enrollment
42 pts
Location
Italy
Sponsor
Fondazione Policlinico Univers
NCT02846571 Phase 1, Phase 2
Recruiting
Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye
Condition
Diabetes
Enrollment
2 pts
Location
United States
Sponsor
Midhat H. Abdulreda
NCT04500899 Phase 1, Phase 2
Recruiting
Use of Phenylephrine for Assessment of Mitral Regurgitation Severity
Condition
Mitral Regurgitation
Enrollment
35 pts
Location
United States
Sponsor
Montefiore Medical Center
NCT06796907 Phase 1, Phase 2
Recruiting
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Ad...
Condition
Tumours, Gynecological
Enrollment
305 pts
Location
United States, Argentina, Australia
Sponsor
GlaxoSmithKline
NCT05417932 Phase 1, Phase 2
Recruiting
A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related He...
Condition
Hepatitis B Virus Related Hepatocellular Carcinoma
Enrollment
46 pts
Location
United States, Hong Kong, Singapore
Sponsor
SCG Cell Therapy Pte. Ltd.
NCT05513872 Phase 1, Phase 2
Recruiting
Overcoming Nicotine Dependence to Enable Quitting
Condition
Tobacco Use
Enrollment
780 pts
Location
United States
Sponsor
Rush University Medical Center
NCT06906471 Phase 1, Phase 2
Recruiting
A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
Condition
Prostate Cancer
Enrollment
10 pts
Location
United States
Sponsor
Antelope Surgical Solutions, I
NCT07105592 Phase 1, Phase 2
Recruiting
A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligibl...
Condition
Head and Neck Squamous Cell Carcinoma
Enrollment
68 pts
Location
China
Sponsor
Fudan University
NCT05006716 Phase 1, Phase 2
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participant...
Condition
B-cell Malignancy
Enrollment
645 pts
Location
United States, Australia, Brazil
Sponsor
BeOne Medicines
NCT06132711 Phase 1, Phase 2
Recruiting
Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multip...
Condition
Multiple Myeloma
Enrollment
20 pts
Location
China
Sponsor
Xuzhou Medical University
NCT05558904 Phase 1, Phase 2
Recruiting
An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Tra...
Condition
Lung Adenocarcinoma
Enrollment
60 pts
Location
United States
Sponsor
Jonsson Comprehensive Cancer C
NCT06303193 Phase 1, Phase 2
Recruiting
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pe...
Condition
Myelodysplastic Syndromes
Enrollment
160 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT05648214 Phase 1, Phase 2
Recruiting
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adu...
Condition
Healthy Volunteers
Enrollment
172 pts
Location
United States
Sponsor
Regeneron Pharmaceuticals
NCT06045910 Phase 1, Phase 2
Recruiting
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Ma...
Condition
Lymphoma, Non-Hodgkin
Enrollment
84 pts
Location
United Kingdom
Sponsor
Cancer Research UK
NCT06101381 Phase 1, Phase 2
Recruiting
CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma
Condition
Leukemia, Acute Lymphoblastic
Enrollment
81 pts
Location
Brazil
Sponsor
University of Sao Paulo
NCT05701306 Phase 1, Phase 2
Recruiting
APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neurobl...
Condition
Neuroblastoma
Enrollment
100 pts
Location
China
Sponsor
Ascentage Pharma Group Inc.
NCT07670468 Phase 1, Phase 2
Recruiting
Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With An...
Condition
BKV Infection
Enrollment
27 pts
Location
South Korea
Sponsor
LucasBio
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology